Pirocarbotrat: a new radiopharmaceutical for the treatment of solid tumors--comparative studies in N-nitrosomethylurea-induced rat mammary tumors.
To evaluate the effectiveness of a single intratumoral dose of Pirocarbotrat, a gelatin-protected charcoal suspension labeled with chromic [32P]pyrophosphate, studies of bioelimination, biodistribution and therapeutic action were carried out in rats, and the results obtained were compared with those of other 32P dispersions. We found that 78.3% of the treated tumors reduced size after 32 days of treatment. At that time, the total eliminated activity was 12.70 +/- 3.90% distributed in urine (8.30 +/- 1.80%) and feces (4.40 +/- 3.50%). Biodistribution studies demonstrate that 84.50 +/- 2.60% of the injected activity remained in the tumor, with no significant concentration in the rest of the organism. We conclude that Pirocarbotrat can be used as a safe agent for brachytherapy of solid tumors with beta particles.
Zubillaga
M B
MB
Radioisotope Laboratory, Facultad de Farmacia y Bioquimica, Buenos Aires, Argentina.
Boccio
J R
JR
Nicolini
J O
JO
Ughetti
R
R
Lanari
E
E
Caro
R A
RA
D000818:Animals; D001610:Beta Particles / Q000627:therapeutic use*; D001918:Brachytherapy; D002606:Charcoal; D011756:Diphosphates / Q000627:therapeutic use*; D005260:Female; D005780:Gelatin; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced / Q000532:radiotherapy*; D008770:Methylnitrosourea; D010761:Phosphorus Radioisotopes / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley
D011756:Diphosphates; D010761:Phosphorus Radioisotopes; D002606:Charcoal; D008770:Methylnitrosourea; D005780:Gelatin